The first biosimilar to receive FDA approval is now available the United States.
Davy James, Managing Editor of Specialty Pharmacy Times
Advertisement
Articles by Davy James, Managing Editor of Specialty Pharmacy Times
The FDA today approved evolocumab (Repatha) injection, a new treatment for patients unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
2
Effectively Managing Immunizations in the Long-Term Care Setting
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
5
